Search Results

By Matthew Stenger  / Tuesday, August 13, 2019 2:35 PM

Response- and Biology-Based Therapy for Pediatric Intermediate-Risk Neuroblastoma

As reported in the Journal of Clinical Oncology by Twist et al, use of reduced therapy for subsets of pediatric patients with intermediate-risk neuroblastoma in the Children’s Oncology Group (COG) study ANBL0531 did not affect the excellent overall survival rates observed in prior COG studies ...